OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March.

Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...

A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

A new computational tool could help researchers identify promising drug combinations for treating cancer, according to a new ...

Harwood works with technology and business leaders to respond to rapid innovation at the intersection of science and technology. His research explores the rise of generative AI and accelerated use of ...

Even well-known drugs can cause entirely unpredictable effects on metabolism, Swiss researchers have shown. Rapidly mapping ...

Scientists have developed retriever, a computational tool that extracts disease-specific drug response signatures to predict the best combinations for cancer treatment.

Scientists from the Cancer Dependency Map (DepMap) at the Broad Institute of MIT and Harvard and Columbia University have ...

AI models are able to design molecules that don’t even exist in nature. Some have proven effective as snake antivenom.

The development is expected to accelerate medical research, drug discovery, ... Google’s new quantum computer signals a potential end to the competition with traditional machines and promises ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger ...